奥米他韦/帕立帕韦/利托那韦加达沙布韦治疗晚期慢性肾病患者 1 型和 4 型 HCV 基因型的疗效和安全性

IF 0.8 Q3 Pharmacology, Toxicology and Pharmaceutics

Journal of Pharmacy and Bioallied Sciences Pub Date : 2024-07-05 DOI:10.4103/jpbs.jpbs_143_24

B. Aljarallah

{"title":"奥米他韦/帕立帕韦/利托那韦加达沙布韦治疗晚期慢性肾病患者 1 型和 4 型 HCV 基因型的疗效和安全性","authors":"B. Aljarallah","doi":"10.4103/jpbs.jpbs_143_24","DOIUrl":null,"url":null,"abstract":"ABSTRACT\n \n This study assessed the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) combined with dasabuvir (DSV) for treating hepatitis C genotype 4 (GT4) and genotype 1 (GT1) in patients with stage 4 or 5 chronic kidney disease (CKD). Among 88 patients, including treatment-naïve and Peginterferon/Ribavirin (RBV)-experienced, treated with OBV/PTV/r±RBV (dosed between 200 mg per week to daily) and additional DSV for GT1, 94.3% achieved sustained virologic response at 12 weeks (SVR12), demonstrating high efficacy. RBV was used at the discretion of the treating physician. The treatment was well-tolerated, with two non-treatment-related deaths reported. The findings suggest that a 12-week regimen of OBV/PTV/r±DSV is highly effective and safe for GT1 and GT4 patients with advanced CKD, regardless of baseline characteristics.","PeriodicalId":16824,"journal":{"name":"Journal of Pharmacy and Bioallied Sciences","volume":" 9","pages":""},"PeriodicalIF":0.8000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease\",\"authors\":\"B. Aljarallah\",\"doi\":\"10.4103/jpbs.jpbs_143_24\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT\\n \\n This study assessed the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) combined with dasabuvir (DSV) for treating hepatitis C genotype 4 (GT4) and genotype 1 (GT1) in patients with stage 4 or 5 chronic kidney disease (CKD). Among 88 patients, including treatment-naïve and Peginterferon/Ribavirin (RBV)-experienced, treated with OBV/PTV/r±RBV (dosed between 200 mg per week to daily) and additional DSV for GT1, 94.3% achieved sustained virologic response at 12 weeks (SVR12), demonstrating high efficacy. RBV was used at the discretion of the treating physician. The treatment was well-tolerated, with two non-treatment-related deaths reported. The findings suggest that a 12-week regimen of OBV/PTV/r±DSV is highly effective and safe for GT1 and GT4 patients with advanced CKD, regardless of baseline characteristics.\",\"PeriodicalId\":16824,\"journal\":{\"name\":\"Journal of Pharmacy and Bioallied Sciences\",\"volume\":\" 9\",\"pages\":\"\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-07-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy and Bioallied Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jpbs.jpbs_143_24\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy and Bioallied Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jpbs.jpbs_143_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

摘要

摘要本研究评估了ombitasvir/paritaprevir/ritonavir（OBV/PTV/r）联合达沙布韦（DSV）治疗4期或5期慢性肾病（CKD）患者丙型肝炎基因型4（GT4）和基因型1（GT1）的疗效和安全性。在 88 例接受 OBV/PTV/r±RBV（剂量从每周 200 毫克到每天 200 毫克不等）治疗并额外使用 DSV 治疗 GT1 的患者中，94.3% 的患者在 12 周后获得了持续病毒学应答（SVR12），显示了很高的疗效。RBV 的使用由主治医生决定。治疗耐受性良好，有两例非治疗相关死亡报告。研究结果表明，无论基线特征如何，为期12周的OBV/PTV/r±DSV治疗方案对晚期CKD的GT1和GT4患者非常有效且安全。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease

ABSTRACT This study assessed the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) combined with dasabuvir (DSV) for treating hepatitis C genotype 4 (GT4) and genotype 1 (GT1) in patients with stage 4 or 5 chronic kidney disease (CKD). Among 88 patients, including treatment-naïve and Peginterferon/Ribavirin (RBV)-experienced, treated with OBV/PTV/r±RBV (dosed between 200 mg per week to daily) and additional DSV for GT1, 94.3% achieved sustained virologic response at 12 weeks (SVR12), demonstrating high efficacy. RBV was used at the discretion of the treating physician. The treatment was well-tolerated, with two non-treatment-related deaths reported. The findings suggest that a 12-week regimen of OBV/PTV/r±DSV is highly effective and safe for GT1 and GT4 patients with advanced CKD, regardless of baseline characteristics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Pharmacy and Bioallied Sciences PHARMACOLOGY & PHARMACY-

CiteScore

1.50

自引率

0.00%

发文量

275

审稿时长

34 weeks

期刊介绍： Journal of Pharmacy And Bioallied Sciences is a Quarterly multidisciplinary open access biomedical journal. Journal of Pharmacy And Bioallied Sciences is an international medium of interaction between scientist, academicians and industrial personnel’s.JPBS is now offial publication of OPUBS.